{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T15:25:48Z","timestamp":1648999548978},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.medcli.2012.10.007","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T04:48:37Z","timestamp":1353473317000},"page":"278-282","source":"Crossref","is-referenced-by-count":1,"title":["Tratamiento del paciente con trombocitemia esencial"],"prefix":"10.1016","volume":"140","author":[{"given":"Gemma","family":"Ramirez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricarda","family":"Garc\u00eda-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2012.10.007_bib0005","series-title":"Hematolog\u00eda Cl\u00ednica","article-title":"S\u00edndromes mieloproliferativos cr\u00f3nicos. Policitemia vera y trombocitemia esencial","author":"Besses","year":"2006"},{"key":"10.1016\/j.medcli.2012.10.007_bib0010","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic critera, survival, and leukemic transition by treatment","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0015","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency of Research on Cancer (IARC); 2008."},{"key":"10.1016\/j.medcli.2012.10.007_bib0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"issue":"Supl 4","key":"10.1016\/j.medcli.2012.10.007_bib0025","first-page":"3","article-title":"Diagn\u00f3stico, pron\u00f3stico y tratamiento de la trombocitemia esencial","volume":"93","author":"Besses","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2012.10.007_bib0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminhematol.2005.05.022","article-title":"Essential trombocythemia","volume":"42","author":"Finazzi","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycytemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.10.007_bib0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","article-title":"Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area","volume":"65","author":"Jensen","year":"2000","journal-title":"Eur J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2012.10.007_bib0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10428199609074360","article-title":"Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia","volume":"22","author":"Michiels","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2012.10.007_bib0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000111776","article-title":"Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia","volume":"118","author":"Cacciola","year":"2007","journal-title":"Acta Haematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/jcp.2004.022178","article-title":"Bone marrow biopsy morbidity: review of 2003","volume":"58","author":"Bain","year":"2005","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u00abresistance\u00bb and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2012.10.007_bib0065","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.007_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Antiplatelet Trialists\u2019","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2012.10.007_bib0075","doi-asserted-by":"crossref","unstructured":"Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"10.1016\/j.medcli.2012.10.007_bib0080","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","article-title":"Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient","volume":"120","author":"Laine","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2012.10.007_bib0085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002296","article-title":"Prevention of NSAID-induced gastroduodenal ulcers","author":"Rostom","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2012.10.007_bib0090","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.10.007_bib0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired von Willebrand disease in patients with high platelet counts","volume":"23","author":"Budde","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.medcli.2012.10.007_bib0100","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0105","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.007_bib0110","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood.V112.11.1746.1746","article-title":"Long-term outcome in polycythemia vera (PV): final analysis of a randomized trial comparing hydroxyurea (HU) to pipobroman(Pi)","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.007_bib0115","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of trombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.10.007_bib0120","unstructured":"Ficha T\u00e9cnica Hydrea. Revisi\u00f3n febrero 2012 [consultado 4 Nov 2012]. Disponible en: http:\/\/www.aemps.gob.es\/cima\/especialidad.do?metodo=verFichaWordPdf&codigo=61633&formato=pdf&formulario=FICHAS&file=ficha.pdf"},{"key":"10.1016\/j.medcli.2012.10.007_bib0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1445-5994.2006.01290.x","article-title":"Effect of hydroxyurea on sperm count, morphology and motility in adult men with sickle cell or myeloproliferative disease","volume":"37","author":"Grigg","year":"2007","journal-title":"Intern Med J"},{"key":"10.1016\/j.medcli.2012.10.007_bib0130","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"Carobbio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.007_bib0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.10.007_bib0140","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0145","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0150","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/sj.leu.2402638","article-title":"Acute myeloid leukaemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea","volume":"16","author":"Bernasconi","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.10.007_bib0155","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0609.1994.tb01303.x","article-title":"Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications","volume":"52","author":"Weinfeld","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukaemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.2830170402","article-title":"Treatment of polycythemia vera with hydroxyurea","volume":"17","author":"Donovan","year":"1984","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-008-0531-7","article-title":"Long-term management of thrombocytosis in essential thrombocythaemia","volume":"88","author":"Birgeg\u00e5rd","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0180","first-page":"A2341","article-title":"Essential thrombocythemia - clinical significance, diagnosis and treatment","volume":"104","author":"Griesshammer","year":"2007","journal-title":"Dtsch Arztebl"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2012.10.007_bib0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","article-title":"Interferon-alpha in the treatment of essential thrombocythemia","volume":"22","author":"Lengfelder","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2012.10.007_bib0190","first-page":"1333","article-title":"Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase ii study","volume":"90","author":"Langer","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2012.10.007_bib0195","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/14656566.1.3.537","article-title":"Anagrelide: a novel agent for the treatment of myeloproliferative disorders","volume":"1","author":"Pescatore","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.medcli.2012.10.007_bib0200","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","article-title":"Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile","volume":"101","author":"Steurer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.medcli.2012.10.007_bib0205","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.leukres.2011.06.030","article-title":"Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia","volume":"35","author":"Gugliotta","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2012.10.007_bib0210","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.leukres.2011.07.031","article-title":"Anagrelide and cardiovascular events. Much ado about nothing?","volume":"35","author":"Besses","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2012.10.007_bib0215","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","article-title":"Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders","volume":"29","author":"Fruchtman","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2012.10.007_bib0220","first-page":"1071","article-title":"Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea","volume":"20","author":"Thiele","year":"2005","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.10.007_bib0280","doi-asserted-by":"crossref","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Final results of the ANAHYDRET study: non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed WHO essential thrombocythemia patients. Blood. 2008;112 [abstract 661].","DOI":"10.1182\/blood.V112.11.661.661"},{"key":"10.1016\/j.medcli.2012.10.007_bib0285","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/leu.2011.306","article-title":"How to manage essential thrombocythemia","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.10.007_bib0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","article-title":"When and how to treat essential thrombocythemia","volume":"353","author":"Barbui","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.10.007_bib0235","unstructured":"SmPCXagrid. Revisi\u00f3n mayo 2011 [consultado 4 Nov 2012]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000480\/WC500056557.pdf"},{"key":"10.1016\/j.medcli.2012.10.007_bib0240","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000189381","article-title":"Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy","volume":"120","author":"Christoforidou","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medcli.2012.10.007_bib0250","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOH.0b013e3283439964","article-title":"Targeting myeloproliferative neoplasms with JAK inhibitors","volume":"18","author":"Pardanani","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0255","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.10.007_bib0260","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0609.2009.01214.x","article-title":"Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies","volume":"82","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0265","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ajh.21504","article-title":"Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry","volume":"84","author":"Melillo","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2012.10.007_bib0270","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (V617F) mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.10.007_bib0275","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2008.03.007","article-title":"Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy","volume":"22","author":"Griesshammer","year":"2008","journal-title":"Blood Rev"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775312008810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775312008810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T11:01:24Z","timestamp":1594897284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775312008810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0025775312008810"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2012.10.007","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}